vs
Side-by-side financial comparison of Aligos Therapeutics, Inc. (ALGS) and ASTROTECH Corp (ASTC). Click either name above to swap in a different company.
Aligos Therapeutics, Inc. is the larger business by last-quarter revenue ($169.0K vs $148.0K, roughly 1.1× ASTROTECH Corp). On growth, ASTROTECH Corp posted the faster year-over-year revenue change (-43.3% vs -72.1%). Over the past eight quarters, ASTROTECH Corp's revenue compounded faster (-40.2% CAGR vs -50.7%).
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel targeted therapies for prevalent liver diseases and viral infections. Its core pipeline includes candidates for chronic hepatitis B, non-alcoholic steatohepatitis, and other liver-related disorders, advancing R&D to serve unmet global patient needs.
Astrotech Corporation, formerly Spacehab Inc., is a technology incubator headquartered in Austin, Texas. Astrotech uses technology sourced internally and from research institutions, government laboratories, and universities to fund, manage and sell start-up companies. Astrotech Corporation's subsidiaries provide commercial products and services to NASA, the U.S. Department of Defense, national space agencies, and global commercial customers.
ALGS vs ASTC — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $169.0K | $148.0K |
| Net Profit | — | $-3.9M |
| Gross Margin | — | 5.4% |
| Operating Margin | — | -2635.8% |
| Net Margin | — | -2653.4% |
| Revenue YoY | -72.1% | -43.3% |
| Net Profit YoY | 75.8% | 2.0% |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $169.0K | $148.0K | ||
| Q3 25 | $741.0K | $297.0K | ||
| Q2 25 | $965.0K | $220.0K | ||
| Q1 25 | $311.0K | $534.0K | ||
| Q4 24 | $606.0K | $261.0K | ||
| Q3 24 | $1.3M | — | ||
| Q2 24 | $1.1M | — | ||
| Q1 24 | $694.0K | — |
| Q4 25 | — | $-3.9M | ||
| Q3 25 | $-31.5M | $-3.5M | ||
| Q2 25 | $-15.9M | $-2.9M | ||
| Q1 25 | $43.1M | $-3.6M | ||
| Q4 24 | $-82.2M | $-4.0M | ||
| Q3 24 | $-19.3M | — | ||
| Q2 24 | $5.1M | — | ||
| Q1 24 | $-34.9M | — |
| Q4 25 | — | 5.4% | ||
| Q3 25 | — | 63.3% | ||
| Q2 25 | — | 33.6% | ||
| Q1 25 | — | 44.4% | ||
| Q4 24 | — | 59.4% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | -2635.8% | ||
| Q3 25 | -3827.4% | -1190.6% | ||
| Q2 25 | -1924.0% | -1326.4% | ||
| Q1 25 | -6187.5% | -724.2% | ||
| Q4 24 | -3393.2% | -1655.6% | ||
| Q3 24 | -1610.5% | — | ||
| Q2 24 | -2489.5% | — | ||
| Q1 24 | -3176.7% | — |
| Q4 25 | — | -2653.4% | ||
| Q3 25 | -4256.0% | -1166.7% | ||
| Q2 25 | -1643.8% | -1331.8% | ||
| Q1 25 | 13854.7% | -680.3% | ||
| Q4 24 | -13556.1% | -1536.0% | ||
| Q3 24 | -1540.7% | — | ||
| Q2 24 | 477.0% | — | ||
| Q1 24 | -5023.5% | — |
| Q4 25 | — | — | ||
| Q3 25 | $-3.04 | — | ||
| Q2 25 | $-1.53 | — | ||
| Q1 25 | $-2.11 | — | ||
| Q4 24 | $-13.10 | — | ||
| Q3 24 | $-3.07 | — | ||
| Q2 24 | $0.81 | — | ||
| Q1 24 | $-5.58 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $77.8M | $7.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $53.5M | $15.5M |
| Total Assets | $88.5M | $19.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $77.8M | $7.0M | ||
| Q3 25 | $99.1M | $11.3M | ||
| Q2 25 | $122.9M | $15.1M | ||
| Q1 25 | $137.9M | $18.1M | ||
| Q4 24 | $56.9M | $21.5M | ||
| Q3 24 | $74.9M | — | ||
| Q2 24 | $94.5M | — | ||
| Q1 24 | $112.7M | — |
| Q4 25 | $53.5M | $15.5M | ||
| Q3 25 | $71.8M | $19.1M | ||
| Q2 25 | $101.9M | $22.1M | ||
| Q1 25 | $116.4M | $24.8M | ||
| Q4 24 | $-29.0M | $28.1M | ||
| Q3 24 | $50.1M | — | ||
| Q2 24 | $67.2M | — | ||
| Q1 24 | $59.8M | — |
| Q4 25 | $88.5M | $19.7M | ||
| Q3 25 | $109.8M | $23.2M | ||
| Q2 25 | $134.7M | $27.0M | ||
| Q1 25 | $150.7M | $27.5M | ||
| Q4 24 | $70.1M | $31.0M | ||
| Q3 24 | $88.4M | — | ||
| Q2 24 | $108.8M | — | ||
| Q1 24 | $127.9M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-82.5M | $-3.5M |
| Free Cash FlowOCF − Capex | — | $-4.0M |
| FCF MarginFCF / Revenue | — | -2671.6% |
| Capex IntensityCapex / Revenue | — | 277.7% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-14.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-82.5M | $-3.5M | ||
| Q3 25 | $-24.3M | $-3.9M | ||
| Q2 25 | $-15.5M | $-2.4M | ||
| Q1 25 | $-20.9M | $-3.9M | ||
| Q4 24 | $-18.4M | $-3.0M | ||
| Q3 24 | $-20.1M | — | ||
| Q2 24 | $-19.5M | — | ||
| Q1 24 | $-22.7M | — |
| Q4 25 | — | $-4.0M | ||
| Q3 25 | — | $-4.4M | ||
| Q2 25 | — | $-2.7M | ||
| Q1 25 | — | $-3.9M | ||
| Q4 24 | — | $-3.4M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | -2671.6% | ||
| Q3 25 | — | -1476.1% | ||
| Q2 25 | — | -1231.4% | ||
| Q1 25 | — | -728.1% | ||
| Q4 24 | — | -1288.5% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 277.7% | ||
| Q3 25 | — | 150.8% | ||
| Q2 25 | — | 158.2% | ||
| Q1 25 | — | 5.1% | ||
| Q4 24 | — | 122.2% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.49× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -3.85× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
